Tapinarof clinical trials
Also written DMVT-505 and WBI-1001.
How each study uses tapinarof is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the tapinarof studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- 23 May 2022 · VTAMA · NDA 215272 (FDA, Drugs@FDA)
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
34 studies that test it; most in 2021 (6)
| Year | Studies |
|---|---|
| 2008 | 1 |
| 2009 | 1 |
| 2010 | 1 |
| 2013 | 1 |
| 2015 | 4 |
| 2017 | 1 |
| 2018 | 1 |
| 2019 | 4 |
| 2021 | 6 |
| 2022 | 3 |
| 2023 | 2 |
| 2024 | 3 |
| 2025 | 3 |
| 2026 | 3 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 24 · Other 10
Organon and Co (12) · GlaxoSmithKline (6) · Welichem Biotech Inc. (3) · Peking University People's Hospital (3) · Indiana University (1) · Sun Pharmaceutical Industries, Inc. (1) · Teva Pharmaceuticals USA (1) · Psoriasis Treatment Center of Central New Jersey (1)
Often tested with
Tested in the same studies.
Betamethasone dipropionate (1) · Betamethasone (1) · Triamcinolone (1) · Fluorouracil (1) · Calcipotriene (1) · Crisaborole (1) · Tacrolimus (1) · Adalimumab (1)
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 4, 2 in phase 3
Studies that test tapinarof, phase 3 first.
- Jan 2027Comparison of Post-Inflammatory Pigment Alteration After Psoriasis Treatment (PIPA - Dermavant)Phase 2/3 · Wake Forest University Health Sciences
- Aug 2027A Study to Investigate Safety and Efficacy of Tapinarof Cream, 1% in Participants Ages 3 Months to < 24 Months With Atopic DermatitisPhase 3 · Organon and Co
- Oct 2027Efficacy and Safety of Benvitimod Cream in Cutaneous T-Cell LymphomaPhase 2 · Peking University First Hospital
- Nov 2027Tapinarof for Cutaneous Lupus ErythematosusEarly Phase 1 · Northwestern University
Studies
Open first, then newest update. How each study uses tapinarof is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 34
- Comparison of Post-Inflammatory Pigment Alteration After Psoriasis Treatment (PIPA - Dermavant)Enrolling by invitationPhase 2/3Wake Forest University Health SciencesNCT05981118Written as Tapinarof
- Efficacy and Safety of Benvitimod Cream in Cutaneous T-Cell LymphomaNot yet recruitingPhase 2Peking University First HospitalNCT07658924Written as Benvitimod Cream
- Efficacy of Topical Tapinarof Versus Betamethasone in the Treatment of Plaque PsoriasisNot yet recruitingPhase 4Pakistan Institute of Medical SciencesNCT07635043Written as Tapinarof Cream 1%
- Utilization of a Microdevice for Psoriasis and Atopic DermatitisNot yet recruitingPhase 4University of California, San FranciscoNCT07352566Written as Tapinarof
- Tapinarof for Cutaneous Lupus ErythematosusEnrolling by invitationEarly Phase 1Northwestern UniversityNCT06661213Written as Tapinarof
- A Study to Investigate Safety and Efficacy of Tapinarof Cream, 1% in Participants Ages 3 Months to < 24 Months With Atopic DermatitisActive, not recruitingPhase 3Organon and CoNCT07265479Written as Tapinarof cream, 1%
- Tapinarof for the Treatment of Plaque Psoriasis in Pediatric SubjectsCompletedPhase 3Organon and CoNCT05172726Written as tapinarof cream, 1%
- Study to Evaluate the Safety and Efficacy of Tapinarof in Adults With Palmoplantar KeratodermaActive, not recruitingPhase 2Indiana UniversityNCT06561321Written as Tapinarof
- A Study Comparing Tapinarof Cream 1% and Vtama® Cream 1% in the Treatment of Plaque Psoriasis.CompletedPhase 1Sun Pharmaceutical Industries, Inc.NCT07546214Written as Tapinarof Cream, 1%
- Study Comparing Tapinarof Cream 1% To VTAMA ® (Tapinarof Cream 1%) In the Treatment of Plaque PsoriasisCompletedPhase 3Teva Pharmaceuticals USANCT06742957Written as Tapinarof Cream 1%
- Maximal Use Study of Tapinarof Cream, 1% in Pediatric Subjects With Extensive Atopic DermatitisCompletedPhase 2Organon and CoNCT05186805Written as Tapinarof cream, 1%
- Tapinarof for the Treatment of Atopic Dermatitis in Children and AdultsCompletedPhase 3Organon and CoNCT05014568Written as tapinarof cream, 1%
- Tapinarof for the Treatment of Atopic Dermatitis in Children and Adults (DMVT-505-3102)CompletedPhase 3Organon and CoNCT05032859Written as tapinarof cream, 1%
- Long Term Extension Study of Tapinarof Cream, 1% for Subjects With Atopic DermatitisCompletedPhase 3Organon and CoNCT05142774Written as Tapinarof cream, 1%
- Long Term Extension Study of Tapinarof for Plaque Psoriasis in Adults (3003)CompletedPhase 3Organon and CoNCT04053387Written as tapinarof cream, 1%
- Maximal Use Study of Tapinarof Cream, 1% in Adults With Extensive Plaque PsoriasisCompletedPhase 2Organon and CoNCT04042103Written as Tapinarof cream, 1%
- Tapinarof for the Treatment of Plaque Psoriasis in Adults (3002)CompletedPhase 3Organon and CoNCT03983980Written as Tapinarof
- A Study to Investigate Efficacy and Safety of VTAMA® (Tapinarof) Cream, 1% in Plaque Psoriasis in the Head and Neck RegionCompletedPhase 4Organon and CoNCT05789576Written as VTAMA (tapinarof) cream, 1%
- A Study to Investigate Efficacy and Safety of VTAMA (Tapinarof) Cream, 1% in Intertriginous Plaque PsoriasisCompletedPhase 4Organon and CoNCT05680740Written as VTAMA® (tapinarof) Cream 1%
- Tapinarof for the Treatment of Plaque Psoriasis in Adults (3001)CompletedPhase 3Organon and CoNCT03956355Written as Tapinarof
Codes
What other systems call tapinarof · ClinicalTrials.gg INT006049
- MeSH (NLM) C571829tapinarofConfirmed ClinicalTrials.gov, NLM
- UNII (FDA) 84HW7D0V04TAPINAROFConfirmed FDA, NLM, Wikidata
- RxNorm 2602286One source FDA
- Wikidata Q76386711tapinarofConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C152511TapinarofOne source FDA
- DrugBank DB06083One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C571829 | tapinarof | Confirmed ClinicalTrials.gov, NLM |
| UNII (FDA) | 84HW7D0V04 | TAPINAROF | Confirmed FDA, NLM, Wikidata |
| RxNorm | 2602286 | — | One source FDA |
| Wikidata | Q76386711 | tapinarof | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C152511 | Tapinarof | One source FDA |
| DrugBank | DB06083 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.